Perdicchi Andrea, Peluso Giacomo, Iacovello Daniela, Balestrieri Marco, Delle Fave Martina, Abdolrahimzadeh Solmaz, Scuderi Gian Luca, Fenicia Vito, Recupero Santi Maria
Ophthalmology Unit, NESMOS Department, Sant'Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
Ophthalmology Unit, Azienda Policlinico Umberto I, "Sapienza" University of Rome, Viale del Policlinico 155, 00186 Rome, Italy.
Biomed Res Int. 2015;2015:268796. doi: 10.1155/2015/268796. Epub 2015 Jun 8.
Purpose. To detect the effects of intravitreal ranibizumab injections on GCC in patients with wet AMD. Methods. 32 wet AMD eyes were selected and submitted at three ranibizumab injections. RTVue-OCT GCC and MM5 protocol were performed before treatment and twenty days after each injection. Results. At baseline mean GCC thickness was 93.9 ± 18.5 μm. Twenty days after each intravitreal injection it was, respectively, 85.8 ± 10.1, 86.5 ± 9.3, and 91.1 ± 11.5 μm, without statistical significance. A significant improvement in visual acuity (P = 0.031) and a reduction of mean foveal (P = 0.001) and macular thickness (P = 0.001) were observed. Conclusion. The clinical results confirm therapeutic efficacy of intravitreal injections of ranibizumab in wet AMD. A contemporary not statistically significant reduction of GCC thickness suggests that the loading phase of ranibizumab does not have any toxic effects on ganglion cell complex.
目的。检测玻璃体内注射雷珠单抗对湿性年龄相关性黄斑变性（wet AMD）患者视网膜神经节细胞复合体（GCC）的影响。方法。选取32只湿性AMD患眼，在进行三次雷珠单抗注射时进行相关检查。在治疗前及每次注射后20天进行RTVue-OCT GCC和MM5检查。结果。基线时平均GCC厚度为93.9±18.5μm。每次玻璃体内注射后20天，其厚度分别为85.8±10.1μm、86.5±9.3μm和91.1±11.5μm，无统计学意义。观察到视力有显著改善（P = 0.031），平均黄斑中心凹厚度（P = 0.001）和黄斑厚度（P = 0.001）降低。结论。临床结果证实玻璃体内注射雷珠单抗对湿性AMD有治疗效果。同时期GCC厚度无统计学意义的降低表明雷珠单抗的负荷阶段对神经节细胞复合体没有任何毒性作用。
